In-hospital mortality after vitamin D supplementation in adults with type 2 diabetes: A pilot feasibility study
Published
July 3, 2024
Paper ID
PAP-000022
Status
Published
DOI
10.65712/tmj.test000280
Advance Services
Abstract
Background: in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes. Methods: Missing data were handled with multiple imputation. Results: in-hospital mortality occurred in 20% of the intervention group versus 19% of controls. The adjusted odds ratio was 0.39 (95% CI 0.27 to 0.63). Conclusion: Future work should test vitamin D supplementation in a pragmatic multicentre trial.
References
1. Silva O, Silva G, et al. Early mobilisation and length of stay. N Engl J Med. 2021;99(5):48-1450.
2. Kim M, Ibrahim C, et al. Tranexamic acid and 30-day readmission. Lancet. 2014;37(4):878-1379.
3. Moreau A, Tanaka A, et al. Tranexamic acid and chronic pain scores. Diabetes Care. 2023;180(11):53-1080.
4. Osei X, Ahmed M, et al. Low-dose aspirin and length of stay. JAMA. 2012;266(9):599-1496.
5. Ahmed J, Patel F, et al. SGLT2 inhibitors and ventilator-free days. JAMA. 2025;244(5):603-1170.
6. Mensah U, Nakamura W, et al. Pharmacist-led medication review and health-related quality of life. BMJ. 2009;326(7):802-1549.
7. Volkov T, Ahmed T, et al. SGLT2 inhibitors and ventilator-free days. Ann Intern Med. 2020;95(1):861-1178.
Introduction
Guidelines make only a weak recommendation on vitamin D supplementation. Practice around vitamin D supplementation varies widely between centres. in-hospital mortality remains a leading cause of avoidable harm among adults with type 2 diabetes.
Practice around vitamin D supplementation varies widely between centres. Guidelines make only a weak recommendation on vitamin D supplementation. The cost of in-hospital mortality to health systems is substantial.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity.
Analyses were adjusted for age, sex and baseline severity.
We conducted a pilot feasibility study across 11 centres between 2015 and 2025. Analyses were adjusted for age, sex and baseline severity.
Results
2766 participants were included (median age 76 years). Serious adverse events were rare and similar between groups.
in-hospital mortality occurred in 11% of the intervention group versus 18% of controls. Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.
3643 participants were included (median age 81 years). 2138 participants were included (median age 42 years). Effects were consistent across prespecified subgroups.
| Group | n | Events |
|---|---|---|
| Male | 85 | 17 |
| Age < 65 | 769 | 112 |
| Female | 178 | 30 |
| Age < 65 | 292 | 90 |
| Male | 516 | 58 |
| Control | 212 | 108 |
| Intervention | 896 | 26 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
3904 participants were included (median age 49 years). 4588 participants were included (median age 35 years). 836 participants were included (median age 35 years). The adjusted odds ratio was 0.66 (95% CI 0.25 to 0.71).
The adjusted odds ratio was 0.79 (95% CI 0.49 to 0.92). 270 participants were included (median age 77 years).
Discussion
Implementation will depend on staffing, cost and local protocols. Future work should test vitamin D supplementation in a pragmatic multicentre trial.
Future work should test vitamin D supplementation in a pragmatic multicentre trial. These findings suggest that vitamin D supplementation is associated with better in-hospital mortality in adults with type 2 diabetes.
Conclusions
Vitamin D supplementation may be offered for adults with type 2 diabetes to improve in-hospital mortality.
Appendices
Supplementary tables are available on request.